The estimated Net Worth of Steve Aselage is at least $8.17 Milión dollars as of 24 May 2024. Steve Aselage owns over 2,500 units of Acer Therapeutics Inc stock worth over $2,250 and over the last 21 years Steve sold ACER stock worth over $8,172,035.
Steve has made over 58 trades of the Acer Therapeutics Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently Steve bought 2,500 units of ACER stock worth $16,000 on 24 May 2024.
The largest trade Steve's ever made was buying 409,836 units of Acer Therapeutics Inc stock on 29 November 2022 worth over $500,000. On average, Steve trades about 10,859 units every 64 days since 2004. As of 24 May 2024 Steve still owns at least 2,500 units of Acer Therapeutics Inc stock.
You can see the complete history of Steve Aselage stock trades at the bottom of the page.
Steve's mailing address filed with the SEC is 4505 EMPEROR BOULEVARD, SUITE 200, DURHAM, NC, 27703.
Over the last 7 years, insiders at Acer Therapeutics Inc have traded over $0 worth of Acer Therapeutics Inc stock and bought 2,078,411 units worth $11,295,691 . The most active insiders traders include Steve Aselage, Chris Schelling a Life Science Ventures Vi Gm.... On average, Acer Therapeutics Inc executives and independent directors trade stock every 165 days with the average trade being worth of $170,051. The most recent stock trade was executed by Chris Schelling on 29 November 2022, trading 819,672 units of ACER stock currently worth $1,000,000.
acer therapeutics is a biotech company, headquartered in cambridge, ma, that develops repurposed and reformulated medicines for the treatment of ultra-orphan diseases with significant unmet medical needs. acer's lead candidate, edviso™ (celiprolol), is the first pharmaceutical therapy seeking approval for patients with vascular-type ehlers-danlos syndrome (veds). ehlers-danlos syndrome is a group of hereditary disorders of connective tissue with no ethnic predisposition. veds is a subtype characterized by severe arterial dissections, ruptures and early death. complications are rare in childhood, but affect 25% of patients before the age of 20, and 80% by the age of 40. median age of death is estimated to be around 50 years. patients are diagnosed by clinical symptoms and confirmed by presence of mutations in the col3a1 gene. there are approximately 2,000 documented patients, but prevalence could be as high as 5,000 patients in the u.s. (pepin 2014). there are no specific pharmacologica
Acer Therapeutics Inc executives and other stock owners filed with the SEC include: